leadf
logo-loader
viewCardiol Therapeutics
(
TSX:CRDLNASDAQ:CRDL
)

Cardiol Therapeutics CEO discusses its clinical studies aimed at heart disease and the coronavirus

Cardiol Therapeutics Inc (TSE:CRDL) (OTCQX:CRTPF) CEO David Elsley talks to Proactive about the Oakville, Ontario-based group's clinical studies aimed at treating inflammatory heart disease. Elsley says its recently completed Phase 1 study with CardiolRx supports its Phase II/III COVID-19 trial in patients with prior history of, or risk factors for, cardiovascular disease and the filing of its IND application with the FDA for an international Phase II trial in acute myocarditis.

Quick facts: Cardiol Therapeutics

Follow
TSX:CRDL

Price: 5.69 CAD

Market Cap: $244.37 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

Cardiol Therapeutics reaches company milestone as they begin trading on the...

Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) CEO David Elsley joined Steve Darling from Proactive to bring news the company has hit a major corporate milestone as they begin trading on the Nasdaq Exchange under the ticker “CRDL” Elsley telling Proactive the company will continue to trade on the...

on 12/8/21

2 min read